# Efficacy and Safety Assessments of a Peritoneal Dialysis Solution Containing Glucose, Xylitol, and L-Carnitine in CAPD

> **NCT04001036** · PHASE2 · TERMINATED · sponsor: **Iperboreal Pharma Srl** · enrollment: 11 (actual)

## Conditions studied

- End Stage Renal Disease

## Interventions

- **DRUG:** 1.5% Xylitol, 0.5% Glucose, and 0.02% L-carnitine
- **DRUG:** 0.7% Xylitol, 0.5% Glucose, and 0.02% L-carnitine

## Key facts

- **NCT ID:** NCT04001036
- **Lead sponsor:** Iperboreal Pharma Srl
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-09-01
- **Primary completion:** 2022-08-30
- **Final completion:** 2022-08-30
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** prematurely interrupted due to significant difficulties in the completion of the sample size defined by the study protocol
- **Last updated:** 2023-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04001036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04001036, "Efficacy and Safety Assessments of a Peritoneal Dialysis Solution Containing Glucose, Xylitol, and L-Carnitine in CAPD". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04001036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*